Today we announced that the U.S. Food and Drug Administration has placed our Phase I/II clinical trial for SGT-001, IGNITE DMD, on Clinical Hold following a serious adverse event that occurred in the first patient dosed, a non-ambulatory adolescent.
Together with Levi Gershkowitz of Living in the Light we are listening to the personal stories of patients and their families in order to better understand the impact that Duchenne muscular dystrophy has on all of our lives and to help inspire the rest of the community.
Marcos and Jesús (9 & 12), Seville, Spain
“I knew what destiny had been written for my children and I was aware that from that moment on, I would spend my life rewriting it.”
Solid Biosciences is dedicated to developing new therapies to improve and extend the lives of patients with Duchenne muscular dystrophy (DMD) with a goal of reaching the largest number of patients in the shortest amount of time.